Amicus’ Pompe disease therapy joins early access scheme
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
Read More
Tag: miglustat
Seven medicines leap closer to EU approval
The European Medicines Agency’s human medicines committee (CHMP) has put forward seven medicines for approval in the region.
Read More
CHMP backs 13 treatments for EU approval
Thirteen new therapies – including two biosimilars – have been backed for approval in Europe.
Read More
Eight medicines leap towards EU approval
Eight medicines – including two biosimilars – have taken a giant step towards being approved for the European market having won favour with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
